Letting post-marketing bridge the evidence gap: The case of orphan drugs

BMJ (Online)

Volumn 353, Issue , 2016, Pages

  Joppi, Roberta ^a,b   Gerardi, Chiara ^a   Bertele, Vittorio ^a   Garattini, Silvio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Local Health Unit of Verona   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; CIXUTUMUMAB; CLADRIBINE; HYDROXYUREA; IBUPROFEN; INDOMETACIN; MITOTANE; ORPHAN DRUG; PARACETAMOL; PHOTOFRIN; PLACEBO; ZINC ACETATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOTOFRIN II; QUINAZOLINE DERIVATIVE;

ARTICLE; COGNITIVE DEFECT; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY IMPAIRMENT; KNOWLEDGE; LICENSING; META ANALYSIS (TOPIC); NECROTIZING ENTEROCOLITIS; NEUROLOGIC DISEASE; PATENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TRANSIENT KIDNEY FAILURE; UNSPECIFIED SIDE EFFECT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; BARRETT ESOPHAGUS; DRUG MANUFACTURE; DUCTUS ARTERIOSUS, PATENT; HEPATOLENTICULAR DEGENERATION; LEUKEMIA, HAIRY CELL; THROMBOCYTHEMIA, ESSENTIAL;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BARRETT ESOPHAGUS; CLADRIBINE; DIHEMATOPORPHYRIN ETHER; DUCTUS ARTERIOSUS, PATENT; HEPATOLENTICULAR DEGENERATION; HUMANS; IBUPROFEN; LEUKEMIA, HAIRY CELL; MITOTANE; ORPHAN DRUG PRODUCTION; PLATELET AGGREGATION INHIBITORS; PRODUCT SURVEILLANCE, POSTMARKETING; QUINAZOLINES; THROMBOCYTHEMIA, ESSENTIAL; ZINC ACETATE;

EID: 84976610769     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i2978     Document Type: Article

References (42)

1. EC. 2000 Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J Eur Communities 2000;L18:1.
2. Joppi R, Bertele' V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2013;69:1009-24. doi:10.1007/s00228-012-1423-2. pmid:23090701.
3. Joppi R, Bertele V, Garattini S. Orphan drug development is progressing too slowly. Br J Clin Pharmacol 2006;61:355-60. doi:10.1111/j.1365-2125.2006.02579.x. pmid:16487232.
4. Joppi R, Bertele V, Garattini S. Orphan drug development is not taking off. Br J Clin Pharmacol 2009;67:494-502. doi:10.1111/j.1365-2125.2009.03369.x. pmid:19552743.
5. EMA. European Medicines Agency assessment report for anagrelide. 2015. http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000480/human-med-001153.jsp&mid=WC0b01ac058001d124
6. Harrison CN, Campbell PJ, Buck G, et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45. doi:10.1056/NEJMoa043800 pmid:16000354.
7. Cacciola RR, Di Francesco E, Pezzella F, Tibullo D, Giustolisi R, Cacciola E. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. Acta Haematol 2007;118:215-8. doi:10.1159/000111776. pmid:18057866.
8. Gisslinger H, Gotic M, Holowiecki J, et al. ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013;121:1720-8. doi:10.1182/blood-2012-07-443770 pmid:23315161.
9. Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ. FOX study investigators. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. Eur J Haematol 2014;92:127-36. doi:10.1111/ejh.12210. pmid:24118452.
10. Schmitz S, Stauch M, Schlag R. Anagrelide for the treatment of thrombocythaemia in daily clinical practice: a post-marketing observational survey on efficacy and safety performed in Germany. Onkologie 2010;33:39-44. doi:10.1159/000264611. pmid:20164660.
11. Steurer MGH, Penka M, Sormann S, et al. Efficacy and safety of anagrelide in the treatment of essential thrombocythemia: data from an international registry. Onkologie 2011;34:206-7.
12. Besses C, Kiladjian JJ, Griesshammer M, et al. Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leuk Res 2013;37:162-8. doi:10.1016/j.leukres.2012.11.004 pmid:23199894.
13. Petrides PE, Gisslinger H, Steurer M, et al. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation. Clin Ther 2009;31:386-98. doi:10.1016/j.clinthera.2009.02.008 pmid:19302911.
14. EMA. European Medicines Agency assessment report for cladribine. 2015. http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000504/human-med-000888.jsp&mid=WC0b01ac058001d124
15. Zenhaüsern R, Schmitz SF, Solenthaler M, et al. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma 2009;50:1501-11. doi:10.1080/10428190903131755 pmid:19672771.
16. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007;109:3672-5. doi:10.1182/blood-2006-08-042929 pmid:17209059.
17. Ravandi F, O'Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011;118:3818-23. doi:10.1182/blood-2011-04-351502 pmid:21821712.
18. EMA. European Medicines Agency assessment report for ibuprofen. 2015. http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000549/human-med-000973.jsp&mid=WC0b01ac058001d124
19. Bagnoli F, Rossetti A, Messina G, Mori A, Casucci M, Tomasini B. Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. J Matern Fetal Neonatal Med 2013;26:423-9. doi:10.3109/14767058.2012.733775. pmid: 23057804.
20. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One 2013;8:e77888. doi:10.1371/journal.pone.0077888. pmid: 24223740.
21. Oncel MY, Yurttutan S, Erdeve O, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr 2014;164:510-4.e1. doi:10.1016/j.jpeds.2013.11.008 pmid:24359938.
22. Lago P, Salvadori S, Opocher F, Ricato S, Chiandetti L, Frigo AC. Continuous infusion of ibuprofen for treatment of patent ductus arteriosus in very low birth weight infants. Neonatology 2014;105:46-54. doi:10.1159/000355679. pmid:24281435.
23. Yadav S, Agarwal S, Maria A, et al. Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. Pediatr Cardiol 2014;35:824-30. doi:10.1007/s00246-014-0861-2 pmid:24435507.
24. Neumann R, Schulzke SM, Bührer C. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology 2012;102:9-15. doi:10.1159/000335332. pmid:22414850.
25. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2013;4:CD003481.pmid:23633310.
26. Eras Z, Gokmen T, Erdeve O, Ozyurt BM, Saridas B, Dilmen U. Impact of oral versus intravenous ibuprofen on neurodevelopmental outcome: a randomized controlled parallel study. Am J Perinatol 2013;30:857-62. doi:10.1055/s-0033-1333667. pmid:23359230.
27. EMA. European Medicines Agency assessment report for mitotane. 2015. http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000521/human-med-000895.jsp&mid=WC0b01ac058001d124
28. Fassnacht M, Terzolo M, Allolio B, et al. FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366:2189-97. doi:10.1056/NEJMoa1200966 pmid:22551107.
29. Lerario AM, Worden FP, Ramm CA, et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer 2014;5:232-9. doi:10.1007/s12672-014-0182-1. pmid:24849545.
30. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005;12:657-66. doi:10.1677/erc.1.01025. pmid:16172198.
31. Fassnacht M, Johanssen S, Fenske W, et al. German ACC Registry Group. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010;95:4925-32. doi:10.1210/jc.2010-0803. pmid:20668036.
32. EMA. European Medicines Agency assessment report for porfimer sodium. 2015. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000493/human-med-000978.jsp&mid=WC0b01ac058001d124
33. Overholt BF, Lightdale CJ, Wang KK, et al. International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-98. doi:10.1016/j.gie.2005.06.047. pmid:16185958.
34. Ragunath K, Krasner N, Raman VS, Haqqani MT, Phillips CJ, Cheung I. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol 2005;40:750-8. doi:10.1080/00365520510015737. pmid:16118910.
35. Dunn JM, Mackenzie GD, Banks MR, et al. A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus. Lasers Med Sci 2013;28:707-15. doi:10.1007/s10103-012-1132-1 pmid:22699800.
36. Nava HR, Allamaneni SS, Dougherty TJ, et al. Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus. Lasers Surg Med 2011;43:705-12. doi:10.1002/lsm.21112. pmid:22057498.
37. Waseem J, David BJQ, Massimo R, et al. Sa1828 Comparison of endotherapies for the treatment of Barrett's dysplasia and neoplasia: what are the ideal modalities? Gastroenterology 2014;146(Suppl 1):S305-6.
38. EMA. European Medicines Agency assessment report for zinc. 2015. http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human-orphan-000142.jsp&mid=WC0b01ac058001d12b
39. Brewer GJ. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. CNS Drugs 2005;19:185-92. doi:10.2165/00023210-200519030-00001. pmid:15740174.
40. Banzi R, Gerardi C, Bertele' V, Garattini S. Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur J Intern Med 2015;26:572-84. doi:10.1016/j.ejim.2015.08.008. pmid: 26342723.
41. EC. Regulation (EC) 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Off J Eur Union 2004;L136:1.
42. Adaptive licensing or adaptive pathways: deregulation under the guise of earlier access. 2015. http://www.isdbweb.org/publications/view/adaptive-licensing-or-adaptive-pathwaysderegulation-under-the-guise-of-earlier-access.